Baseline demographic and clinical characteristics
| . | Komodo (1 January 2015-30 April 2023) . | Acentrus (1 January 2016-30 April 2022) . | ||
|---|---|---|---|---|
| Overall population . | High CV risk subgroup∗ . | Overall population . | High CV risk subgroup∗ . | |
| n = 3342 . | n = 2640 . | n = 1171 . | n = 724 . | |
| Age (y) at index date, mean ± SD | 67.5 ± 10.6 | 69.4 ± 10.3 | 70.4 ± 9.9 | 75.0 ± 7.8 |
| Female, n (%) | 1258 (37.6) | 993 (37.6) | 405 (34.6) | 239 (33.0) |
| Year of index date, n (%) | ||||
| 2016 | 403 (12.1) | 315 (11.9) | - | |
| 2017 | 724 (21.7) | 579 (21.9) | 82 (7.0) | 48 (6.6) |
| 2018 | 552 (16.5) | 441 (16.7) | 285 (24.3) | 155 (21.4) |
| 2019 | 449 (13.4) | 347 (13.1) | 359 (30.7) | 233 (32.2) |
| 2020 | 515 (15.4) | 401 (15.2) | 275 (23.5) | 183 (25.3) |
| 2021 | 397 (11.9) | 315 (11.9) | 136 (11.6) | 85 (11.7) |
| 2022 | 273 (8.2) | 215 (8.1) | 34 (2.9) | 20 (2.8) |
| 2023 | 29 (0.9) | 27 (1.0) | - | - |
| US region, n (%) | ||||
| West | 521 (15.6) | 390 (14.8) | 394 (33.6) | 210 (29.0) |
| South | 1021 (30.6) | 814 (30.8) | 323 (27.6) | 205 (28.3) |
| Midwest | 829 (24.8) | 653 (24.7) | 305 (26.0) | 221 (30.5) |
| Northeast | 845 (25.3) | 684 (25.9) | 36 (3.1) | 20 (2.8) |
| Puerto Rico | 7 (0.2) | 6 (0.2) | - | - |
| Unknown | 119 (3.6) | 93 (3.5) | 113 (9.6) | 68 (9.4) |
| Quan-CCI,† mean ± SD | 3.0 ± 1.5 | 3.1 ± 1.6 | 3.0 ± 1.7 | 3.5 ± 1.9 |
| Comorbidities, n (%) | ||||
| Patients at high risk of a CV event∗ | 2640 (79.0) | 2640 (100.0) | 724 (61.8) | 724 (100.0) |
| Valvular disease | 351 (10.5) | 351 (13.3) | 58 (5.0) | 54 (7.5) |
| Renal impairment/dialysis | 218 (6.5) | 197 (7.5) | 47 (4.0) | 43 (5.9) |
| Atrial fibrillation | 254 (7.6) | 254 (9.6) | 85 (7.3) | 85 (11.7) |
| Insurance coverage, n (%) | ||||
| Medicare | 1180 (35.3) | 1077 (40.8) | 278 (23.7) | 202 (27.9) |
| Commercial | 1094 (32.7) | 731 (27.7) | - | - |
| Managed Care | - | - | 100 (8.5) | 31 (4.3) |
| Medicaid | 221 (6.6) | 181 (6.9) | 18 (1.5) | 5 (0.7) |
| Other | 574 (17.1) | 431 (16.3) | 414 (35.4) | 249 (34.4) |
| Unknown | 273 (8.2) | 220 (8.3) | 361 (30.8) | 237 (32.7) |
| Race, n (%) | ||||
| White | - | - | 510 (43.6) | 317 (43.8) |
| Black | - | - | 53 (4.5) | 39 (5.4) |
| Asian | - | - | 34 (2.9) | 22 (3.0) |
| Other | - | - | 574 (49.0) | 346 (47.8) |
| . | Komodo (1 January 2015-30 April 2023) . | Acentrus (1 January 2016-30 April 2022) . | ||
|---|---|---|---|---|
| Overall population . | High CV risk subgroup∗ . | Overall population . | High CV risk subgroup∗ . | |
| n = 3342 . | n = 2640 . | n = 1171 . | n = 724 . | |
| Age (y) at index date, mean ± SD | 67.5 ± 10.6 | 69.4 ± 10.3 | 70.4 ± 9.9 | 75.0 ± 7.8 |
| Female, n (%) | 1258 (37.6) | 993 (37.6) | 405 (34.6) | 239 (33.0) |
| Year of index date, n (%) | ||||
| 2016 | 403 (12.1) | 315 (11.9) | - | |
| 2017 | 724 (21.7) | 579 (21.9) | 82 (7.0) | 48 (6.6) |
| 2018 | 552 (16.5) | 441 (16.7) | 285 (24.3) | 155 (21.4) |
| 2019 | 449 (13.4) | 347 (13.1) | 359 (30.7) | 233 (32.2) |
| 2020 | 515 (15.4) | 401 (15.2) | 275 (23.5) | 183 (25.3) |
| 2021 | 397 (11.9) | 315 (11.9) | 136 (11.6) | 85 (11.7) |
| 2022 | 273 (8.2) | 215 (8.1) | 34 (2.9) | 20 (2.8) |
| 2023 | 29 (0.9) | 27 (1.0) | - | - |
| US region, n (%) | ||||
| West | 521 (15.6) | 390 (14.8) | 394 (33.6) | 210 (29.0) |
| South | 1021 (30.6) | 814 (30.8) | 323 (27.6) | 205 (28.3) |
| Midwest | 829 (24.8) | 653 (24.7) | 305 (26.0) | 221 (30.5) |
| Northeast | 845 (25.3) | 684 (25.9) | 36 (3.1) | 20 (2.8) |
| Puerto Rico | 7 (0.2) | 6 (0.2) | - | - |
| Unknown | 119 (3.6) | 93 (3.5) | 113 (9.6) | 68 (9.4) |
| Quan-CCI,† mean ± SD | 3.0 ± 1.5 | 3.1 ± 1.6 | 3.0 ± 1.7 | 3.5 ± 1.9 |
| Comorbidities, n (%) | ||||
| Patients at high risk of a CV event∗ | 2640 (79.0) | 2640 (100.0) | 724 (61.8) | 724 (100.0) |
| Valvular disease | 351 (10.5) | 351 (13.3) | 58 (5.0) | 54 (7.5) |
| Renal impairment/dialysis | 218 (6.5) | 197 (7.5) | 47 (4.0) | 43 (5.9) |
| Atrial fibrillation | 254 (7.6) | 254 (9.6) | 85 (7.3) | 85 (11.7) |
| Insurance coverage, n (%) | ||||
| Medicare | 1180 (35.3) | 1077 (40.8) | 278 (23.7) | 202 (27.9) |
| Commercial | 1094 (32.7) | 731 (27.7) | - | - |
| Managed Care | - | - | 100 (8.5) | 31 (4.3) |
| Medicaid | 221 (6.6) | 181 (6.9) | 18 (1.5) | 5 (0.7) |
| Other | 574 (17.1) | 431 (16.3) | 414 (35.4) | 249 (34.4) |
| Unknown | 273 (8.2) | 220 (8.3) | 361 (30.8) | 237 (32.7) |
| Race, n (%) | ||||
| White | - | - | 510 (43.6) | 317 (43.8) |
| Black | - | - | 53 (4.5) | 39 (5.4) |
| Asian | - | - | 34 (2.9) | 22 (3.0) |
| Other | - | - | 574 (49.0) | 346 (47.8) |
Demographic characteristics were evaluated on the date of treatment initiation. Clinical characteristics were evaluated in the 12-month baseline period.
SD, standard deviation.
See supplemental Table 2 for details regarding the definition of patients at high risk for a CV event.
Reference: Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-682.